⌕
Cogent Biosciences · COGT · Nasdaq
$28.56at last closeTenet 33 · Weak
Compare
$28.56at last closeTenet 33 · Weak

Cogent Biosciences (COGT) Stock

Cogent Biosciences (COGT) has a Tenet Score of 33 of 100 against 313 Healthcare peers, as of Nov 13, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Key stats

Market cap
$5.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
Tenet Score
33/100
Weak · 313 Healthcare peers

Industry: Drugs

Cogent Biosciences Inc scores 33/100. Weak. Strongest on financial health, quality is the soft spot versus 313 Healthcare peers. Insufficient inputs: Tenet 33 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=313
33/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
15
Quality
11
Health
72
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth & Momentum omitted — no data yet.
ValueFQualityFHealthBGrowth—Momentum—
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
11.0×
price to book value
P/S
—
no P/S on file
ROE
−126%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
10.99
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file
52-wk range
—
no 52-week range on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 82 US ETFs · top wrappers by weightSee all ETFs holding COGT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Cogent Biosciences in?

Cogent Biosciences is in the Healthcare sector and the Drugs industry.

What is Cogent Biosciences' Tenet Score?

Cogent Biosciences' Tenet Score is 33 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.